| 1 |
Gabrielli A. Scleroderma[J]. N Engl J Med, 2009, 360(19): 1989-2003.
|
| 2 |
Barnes J, Mayes MD. Epidemiology of systemic sclerosis：incidence, prevalence, survival, riskfactors, malignancy, and environmental triggers[J]. Curr Opin Rheumatol, 2012, 24(2): 165-170.
|
| 3 |
Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era[J]. Ann Rheum Dis, 2013, 72(12): 1940-1946.
|
| 4 |
Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002[J]. Ann Rheum Dis, 2007, 66(7): 940.
|
| 5 |
Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis[J]. Autoimmun Rev, 2010, 9(5): A311-A318.
|
| 6 |
Akter T, Silver RM, Bogatkevich GS. Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease[J]. Curr Rheumatol Rep, 2014, 16(4): 411.
|
| 7 |
Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis[J]. Ann Rheum Dis, 2017, 76: 1897-905.
|
| 8 |
Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research(EUSTAR) database[J]. Ann Rheum Dis, 2010, 69(10): 1809.
|
| 9 |
Volkmann ER, Tashkin DP, Sim M, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts[J]. Ann Rheum Dis, 2019, 78(1): 122-130.
|
| 10 |
Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis[J]. Arthritis Rheumatol, 2017, 69(8): 1670-1678.
|
| 11 |
Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system[J]. Am J Respir Crit Care Med, 2008, 177: 1248-1254.
|
| 12 |
Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival[J]. Chest, 2008, 134(3): 601-605.
|
| 13 |
Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2002, 19(2): 121-127.
|
| 14 |
Okamoto M, Fujimoto K, Sadohara J, et al. A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease[J]. Respir Investig, 2016, 54(6): 445-453.
|
| 15 |
Solomon JJ, Olson AL, Fischer A, et al. Scleroderma lung disease[J]. Eur Respir Rev, 2013, 22: 6-19.
|
| 16 |
Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease[J]. N Engl J Med, 2006, 354: 2655-2666.
|
| 17 |
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017, 76(8): 1327-1339.
|
| 18 |
Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease[J]. Am J Respir Crit Care Med, 2007, 176(10): 1026-1034.
|
| 19 |
Tashkin DP, Roth MD, Clements PJ, et al. Sclerodema Lung Study Ⅱ Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS Ⅱ): a randomised controlled, double-blind, parallel group trial[J]. Lancet Respir Med, 2016, 4: 708-719.
|
| 20 |
Dheda K, Lalloo UG, Cassim B, et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease[J]. Clin Rheumatol, 2004, 23: 306-309.
|
| 21 |
Nadashkevich O, Davis P, Fritzler M, et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis[J]. Clin Rheumatol, 2006, 25: 205-212.
|
| 22 |
Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) Group[J]. Ann Rheum Dis, 2015, 74: 1188-1194.
|
| 23 |
Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study[J]. Rheumatology (Oxford, England), 2010, 49: 271-280.
|
| 24 |
Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter，open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease[J]. Semin Arthritis Rheum, 2017, 46(5): 625-631.
|
| 25 |
Sari A, Guven D, Armagan B, et al. Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: a series of 14 patients[J]. J Clin Rheumatol, 2017, 23(8): 411-415.
|
| 26 |
Miura Y, Saito T, Fujita K, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2014, 31(3): 235-238.
|
| 27 |
Khanna D, Albera C, Fischer A, et al. An Open-label, Phase Ⅱ Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LO-TUSS Trial [J]. J Rheumatol, 2016, 43(9): 1672-1679.
|
| 28 |
Bendstrup E, Wuyts W, Alfaro T, et al. Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events[J]. Respiration, 2019, 97(2): 173-184.
|
| 29 |
Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis[J]. Ann Rheum Dis, 2016, 75: 883-890.
|
| 30 |
Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis[J]. Ann Rheum Dis, 2017, 76: 1941-1948.
|
| 31 |
Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis[J]. J Pharmacol Exp Ther, 2014, 349: 209-220.
|
| 32 |
Host L, Nikpour M, Calderone A, et al. Autologous stem cell transplantation in systemic sclerosis: a systematic review[J]. Clin Exp Rheumatol, 2017, 106(4): 198-207.
|
| 33 |
Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial[J]. Lancet, 2011, 378: 498-506.
|
| 34 |
Van Laar JM, Farge D, Sont JK, et al. EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial[J]. JAMA, 2014, 311: 2490-2498.
|
| 35 |
Miele CH, Schwab K, Saggar R, et al. Lung Transplant Out-comes in Systemic Sclerosis with Significant Esophageal Dys-function. A Comprehensive Single-Center Experience[J]. Ann Am Thorac Soc, 2016, 13(6): 793-802.
|
| 36 |
Garca-Hernandez FJ, Castillo-Palma MJ, Tolosa-Vilella C, et al. Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry[J]. Clin Rheumatol, 2019, 38(4): 1117-1124.
|
| 37 |
Niklas K, Niklas A, Mularek-Kubzdela T, et al. Prevalence of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease[J]. Medicine (Baltimore), 2018, 97(28): e11437.
|
| 38 |
Sundaram SM, Chung L. An update on systemic sclerosis-associated pulmonary arterial hypertension: a review of the current literature[J]. Curr Rheumatol Rep, 2018, 20(2): 10.
|
| 39 |
Morrisroe K, Stevens W, Sahhar J, et al. Australian Scleroderma Interest Group (ASIG). Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme[J]. Arthritis Res Ther, 2017, 19(1): 42.
|
| 40 |
Ramjug S, Hussain N, Hurdman J, et al. Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes[J]. Chest, 2017, 152(1): 92-102.
|
| 41 |
Coghlan JG, Denton CP, Grunig E, et al. DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study[J]. Ann Rheum Dis, 2014, 73: 1340-1349.
|
| 42 |
Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: Chest guideline and expert panel report[J]. Chest, 2014, 146: 449-475.
|
| 43 |
Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Revistaespanola de Cardiologia (English ed.), 2016, 69: 177.
|
| 44 |
McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association[J]. Circulation, 2009, 119: 2250-2294.
|